Search Results for "miglitol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for miglitol. Results 1 to 5 of 5 total matches.
See also: Glyset
Miglitol for Type 2 Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • May 21, 1999 (Issue 1053)
Miglitol for Type 2 Diabetes Mellitus ...
Miglitol, an oral alpha-glucosidase inhibitor similar to acarbase, is now available for treatment of type 2 diabetes.
Rosiglitazone for Type 2 Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • Aug 13, 1999 (Issue 1059)
Acarbose − Precose (Bayer) 50 to 100 mg tid with meals 46.54
Miglitol − Glyset (Pharmacia & Upjohn) 50 ...
Rosiglitazone, the second thiazolidinedione derivative to be marketed in the USA for treatment of type 2 diabetes, has been approved by the FDA for use either alone or combined with meformin.
Nateglinide For Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 02, 2001 (Issue 1101)
Inhibitors
Acarbose − Precose (Bayer) 50 to 100 mg t.i.d. with meals $ 48.60
Miglitol − Glyset (Pharmacia ...
Nateglinide (Starlix), a new meglitinide oral glucose-lowering agent, has been approved by the FDA.
Pramlintide (Symlin) for Diabetes
The Medical Letter on Drugs and Therapeutics • May 23, 2005 (Issue 1209)
) or miglitol (Glyset). The package insert
states that mixing pramlintide in the same syringe with
insulin ...
Pramlintide acetate (Symlin - Amylin Pharmaceuticals), a synthetic analog of human amylin, has been approved by the FDA as adjunctive treatment for patients with type 1 or type 2 diabetes who inject insulin at mealtimes and have failed to achieve glucose control. Pramlintide is injected subcutaneously before meals.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
tid4,36 41.30
Miglitol – generic 25, 50, 100 mg tabs 50-100 mg PO tid4,37 291.40
ER = extended ...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.